Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Change in Receivables (2023 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Change in Receivables for 3 consecutive years, with $15.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Receivables rose 15.58% to $15.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $13.1 million, a 81.05% decrease, with the full-year FY2025 number at $13.1 million, down 81.05% from a year prior.
  • Change in Receivables was $15.7 million for Q4 2025 at Iovance Biotherapeutics, up from $6.8 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $31.4 million in Q2 2024 to a low of -$11.0 million in Q2 2025.
  • A 3-year average of $7.5 million and a median of $1.6 million in 2025 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: surged 94960.61% in 2024, then tumbled 135.07% in 2025.
  • Iovance Biotherapeutics' Change in Receivables stood at $149000.0 in 2023, then surged by 9008.72% to $13.6 million in 2024, then increased by 15.58% to $15.7 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Change in Receivables are $15.7 million (Q4 2025), $6.8 million (Q3 2025), and -$11.0 million (Q2 2025).